title: OPA1 in Cardiovascular Health and Disease.
abstract: Mitochondria are known to play crucial roles in normal cellular physiology and in more recent years they have been implicated in a wide range of pathologies. Central to both these roles is their ability to alter their shape interchangeably between two different morphologies: an elongated interconnected network and a fragmented discrete phenotype - processes which are under the regulation of the mitochondrial fusion and fission proteins, respectively. In this review article, we focus on the mitochondrial fusion protein optic atrophy protein 1 (OPA1) in cardiovascular health and disease and we explore its role as a potential therapeutic target for treating cardiovascular and metabolic disease.
authors.forename: Niall
authors.initials: N
authors.lastname: Burke
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Hall
authors.affiliation: The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK. d.hausenloy@ucl.ac.uk.
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Hausenloy
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism*; D015536:Down-Regulation; D020558:GTP Phosphohydrolases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy / Q000378:metabolism*; D008928:Mitochondria / Q000378:metabolism / Q000502:physiology; D058990:Molecular Targeted Therapy
chemical_list: D020558:GTP Phosphohydrolases; C415198:OPA1 protein, human